---
title: Medical Device Regulation in South Korea (MFDS): APAC Access
description: South Korea MFDS medical device approval for EU startups: classification, KGMP audits, local representative, Korean clinical data expectations and timelines.
authors: Tibor Zechmeister, Felix Lenhard
category: FDA & International Market Access
primary_keyword: South Korea MFDS medical device
canonical_url: https://zechmeister-solutions.com/en/blog/south-korea-mfds-medical-device
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# Medical Device Regulation in South Korea (MFDS): APAC Access

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **The South Korea MFDS medical device framework is run by the Ministry of Food and Drug Safety under the Korean Medical Device Act. Devices are placed in four risk classes (I–IV), manufacturers need a Korean local representative (K-License holder), and Class II and above require a Korea Good Manufacturing Practice (KGMP) audit plus Korean-language technical and clinical documentation.**

**By Tibor Zechmeister and Felix Lenhard.**

## TL;DR
- South Korea regulates medical devices through the Ministry of Food and Drug Safety (MFDS) under the Medical Device Act .
- Classification follows a GHTF-aligned four-tier risk system: Class I, II, III, IV, with approval pathway and fees scaling by class.
- A Korean local representative (often called the Korea License Holder or KLH) is mandatory for foreign manufacturers — the KLH holds the registration.
- KGMP (Korea GMP) certification is required before product approval for Class II, III, IV. A joint MFDS/third-party on-site audit is the norm.
- Korean clinical data expectations are rising: MFDS increasingly asks for Korean-population data or robust bridging rationale for novel devices.
- Realistic timelines for a first Korean registration: 9–18 months depending on class and whether clinical trials are needed.

## Why this matters

South Korea is one of the top three medical device markets in Asia-Pacific and — together with Japan — the most mature. For EU MedTech founders, it is often the second or third international step after CE and US FDA. The attraction is real: a sophisticated hospital system, a tech-literate population, and public reimbursement pathways that actually exist. The catch is that MFDS does not simply accept your CE technical file. You will re-document, re-audit, and in many cases re-generate clinical evidence.

Tibor has walked several startups through the sequencing conversation: *CE first, then FDA, then Korea — or Korea before FDA?* The right answer depends on where your beachhead customers are, not on which regulator looks friendliest. Felix's Subtract to Ship lens is unforgiving here: if Korea is not in your first 24 months of revenue, do not start MFDS paperwork yet. Every document you open is a document you have to maintain.

This post maps what MFDS actually asks for, how it compares to MDR, and where the real time and money go.

## What the Korean framework actually says

South Korea's medical device regulation rests on three pillars:

1. **The Medical Device Act and its Enforcement Decree and Rules** — the primary legislation governing scope, classification, registration, and post-market obligations .
2. **MFDS notifications and guidelines** — the operational detail, updated regularly, covering technical documentation, clinical evaluation, KGMP, labeling, and UDI.
3. **KGMP (Korea Good Manufacturing Practice)** — the quality system standard that maps closely to ISO 13485 but has Korea-specific add-ons, particularly around documentation language and local representative responsibilities.

**Classification.** MFDS uses four classes aligned broadly with GHTF/IMDRF principles:

- **Class I** — low risk. Notification only, no clinical data, no KGMP audit for most items.
- **Class II** — low-to-moderate risk. Certification through a third-party organization designated by MFDS, KGMP required.
- **Class III** — moderate-to-high risk. Approval directly by MFDS, KGMP required, clinical data usually required.
- **Class IV** — high risk, including implantables and life-supporting devices. MFDS approval, KGMP, clinical trials typically required.

The class does not always match MDR. A Class IIa device under MDR can land in Korean Class III if it touches a higher-risk rule category, and vice versa. Do the Korean classification exercise independently — do not assume your MDR class maps one-to-one .

**Local representative.** Under the Medical Device Act, a foreign manufacturer cannot hold a Korean registration directly. A Korean-resident entity — the K-License Holder — holds the approval on your behalf. This is legally and commercially significant: switching KLHs later is painful, because the license is tied to that entity.

**Clinical data.** For novel devices and higher classes, MFDS expects either Korean clinical study data or a well-argued bridging rationale using foreign data. The Korea Medical Device Information & Technology Assistance Center (often shortened KMDIA) supports manufacturers navigating these clinical and technical consultations .

**KGMP audit.** For Class II and above, a KGMP audit is required before market approval. It can be conducted jointly by MFDS and a designated third-party certification body, often combined with ISO 13485 audits to reduce travel and cost.

## A worked example

A Vienna-based startup has CE marking for a Class IIa wound care device with a sensor patch. They want to expand into South Korea because a large Seoul hospital group has expressed interest.

- **Classification.** Under Korean rules, the sensor-patch combination lands in Class III (not Class IIa as in the EU), because of the continuous monitoring claim and the specific rule category.
- **KLH selection.** They contract a mid-sized Korean distributor who also provides KLH services. Contract carefully negotiates that the license can be transferred to a different KLH with written notice — this is the single most important clause.
- **KGMP preparation.** Their existing ISO 13485 QMS is about 80 percent of the way there. The gap is Korean-language document control, Korean complaint-handling procedures, and KLH-specific responsibilities in their QMS.
- **Clinical data.** Their EU clinical evaluation under MDR Article 61 relied on literature plus a small post-market study. MFDS requests a Korean clinical bridging study of roughly 60 patients at two local hospitals.
- **Timeline.** 4 months for classification confirmation and KLH setup, 3 months KGMP readiness, 2 months KGMP audit and response, 6 months clinical bridging study, 4 months MFDS review. Total: about 19 months. Budget: roughly EUR 180,000–250,000 including the Korean study, KGMP audit, translation, and KLH fees.

This is not cheap. And it is not fast. But it is honest — and it is the cost of entering a market that, once you are in, can scale.

## The Subtract to Ship playbook

1. **Decide Korea is real before you open a single file.** If Korea is not in your 24-month revenue plan, park it. Write "Korea: not yet" on your regulatory roadmap and move on. Every document you start, you must maintain forever.
2. **Do the Korean classification first.** Before anything else, map your device against the Korean rules and confirm the class. Classification errors are the single biggest source of wasted effort here.
3. **Select the KLH with the same care as a co-founder.** The KLH is effectively your legal identity in Korea. Check references. Require contractual rights to transfer the license. Understand their vigilance and complaint-handling capacity.
4. **Reuse your MDR QMS, do not rebuild it.** KGMP and ISO 13485 share 80 percent of their DNA. Build Korean-specific procedures as a KGMP annex to your existing QMS rather than as a parallel system. Have your ISO 13485 certification body quote on a joint audit when timing allows.
5. **Negotiate clinical evidence expectations early.** Request a pre-submission consultation with MFDS (via KMDIA or your KLH) to confirm whether your EU/US clinical evidence is acceptable as a bridge or whether a Korean study is required. Doing this before you draft a protocol can save 6–12 months.
6. **Translate once, translate well.** Korean technical and labeling translation is a specialist job. Budget for a medical translator with regulatory experience, and include terminology review by a Korean clinician. Cheap translation is the fastest way to a round of deficiency questions.
7. **Sequence Korea after CE plus one other market.** Tibor's recommendation: do not make Korea your first international expansion after CE. Use FDA or a smaller Asian market (Singapore, Taiwan) first to build international registration muscle.

## Reality Check

1. Do you have a written Korean device classification (not just an assumption based on your MDR class)?
2. Is your KLH candidate vetted, referenced, and under a contract that allows license transfer?
3. Does your QMS explicitly cover KGMP-specific requirements, including Korean-language document control?
4. Have you confirmed with MFDS — in writing or via pre-submission — whether your existing clinical data is acceptable, or whether a Korean study is needed?
5. Do you have a named, realistic budget line for translation, KGMP audit, KLH fees, and potential clinical work?
6. Can you maintain Korean post-market surveillance and vigilance reporting in parallel with your EU obligations without breaking your team?
7. Is your Korean launch customer committed in writing, or is it still a maybe?
8. If Korea disappeared from your roadmap tomorrow, would your business plan still work?

If you answered "no" or "not sure" to three or more of these, Korea is not ready for you yet. That is fine. Subtract it. Ship the parts you can.

## Frequently Asked Questions

**Does my CE certificate count in Korea?**
No. MFDS recognizes CE marking as supporting evidence but does not grant any automatic approval based on it. You must go through the full Korean registration pathway, including Korean technical documentation and — for most classes — KGMP certification and clinical data review.

**Can my EU Authorized Representative act as my Korean KLH?**
No. The Korean License Holder must be a Korea-resident legal entity. Your EU AR under MDR Article 11 has no Korean role. These are two separate, legally distinct relationships.

**How long does MFDS review typically take?**
For Class II, expect roughly 3–6 months of administrative review after KGMP certification. For Class III and IV, budget 6–12 months of review on top of KGMP and clinical activities. Clock stops during deficiency responses.

**Is KGMP the same as ISO 13485?**
No, but close. KGMP is built on ISO 13485 principles with Korea-specific additions around local language documentation, KLH responsibilities, and some record-keeping. A well-run ISO 13485 QMS covers most of the ground; the delta is procedural and linguistic.

**Do I need Korean clinical trials for every device?**
No. Class I and many Class II devices do not require Korean clinical data. For novel Class III and IV devices, and for devices without clear Korean predicates, MFDS often requires Korean bridging studies — but this should be confirmed through pre-submission consultation rather than assumed.

**What is the fastest realistic timeline for a first Korean approval?**
For a straightforward Class II device with solid CE documentation and a prepared KLH: roughly 9–12 months. For Class III or IV with Korean clinical studies: 18–30 months. Anything faster than this is optimistic.

## Related reading
- [International expansion sequencing](/blog/international-expansion-sequencing) — how to order CE, FDA, and APAC markets without wasting cash.
- [Prioritize international markets for medtech](/blog/prioritize-international-markets-medtech) — a framework for deciding which market is actually next.
- [Regulatory strategy for global market access](/blog/regulatory-strategy-global-market-access) — the big picture before you open any national file.
- [IMDRF global harmonization for startups](/blog/imdrf-global-harmonization-startups) — where Korea aligns with international norms and where it does not.
- [MDSAP: single audit for multiple markets](/blog/mdsap-single-audit-multiple-markets) — why Korea is not part of MDSAP and what that means for your audit calendar.

## Sources
1. Republic of Korea, Medical Device Act and Enforcement Decree/Rules .
2. Ministry of Food and Drug Safety (MFDS), medical device classification and KGMP notifications.
3. Regulation (EU) 2017/745 on medical devices, Articles 10, 11, Annex IX (for MDR comparison points only).
4. EN ISO 13485:2016+A11:2021 — QMS (referenced for KGMP comparison).

---

*This post is part of the [FDA & International Market Access](https://zechmeister-solutions.com/en/blog/category/fda-international) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*